Market Research Logo

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Industry Analysis & Outlook (2018-2025)

Global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market: Industry Analysis & Outlook (2018-2025)

PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.

PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.

The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.

The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts. However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.

The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers and challenges of the market, covering the U.S. and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc. are being profiled along with their key financials and strategies for growth.


1. Market Overview
1.1 DNA Damage Response (DDR)
1.2 DNA Repair Pathways
1.3 PARP Inhibitor
Table 1: Role of PARP
1.4 Inhibiting PARP Mechanism
Table 2: PARP Inhibitor Mechanism
1.5 PARP for Cancer Treatment
1.6 PARP Inhibitor Drugs
Table 3: Key PARP Inhibitors in Development
2. Global Market Analysis
2.1 Global PARP Inhibitor Market
2.1.1 Global PARP Inhibitor Market Forecast by Value
Table 4: Global PARP Inhibitor Market Forecast by Value (2017-2025)
2.1.2 Global PARP Inhibitor Market Forecast by Cancer Type
Table 5: Global PARP Inhibitor Market Forecast by Cancer Type (2017-2025)
2.1.3 Global PARP Inhibitor Market Share Forecast by Cancer Type
Table 6: Global PARP Inhibitor Market Share Forecast by Cancer Type (2020/2025)
2.2 Global PARP Inhibitor Market by Drug Type
Table 7: Global PARP Inhibitor Market by Drug Type (2017)
2.2.1 Global Lynparza Market Forecast by Value
Table 8: Global Lynparza Market Forecast by Value (2017-2025)
2.2.2 Global Lynparza Market Forecast by Cancer Type
Table 9: Global Lynparza Market Forecast by Cancer Type (2017-2025)
2.2.3 Global Lynparza Market Forecast by Region
Table 10: Global Lynparza Market Forecast by Region (2017)
2.2.4 Global Rubraca Market Forecast by Value
Table 11: Global Rubraca Market Forecast by Value (2017-2025)
2.2.5 Global Rubraca Market Forecast by Cancer Type
Table 12: Global Rubraca Market Forecast by Cancer Type (2017-2025)
2.2.6 Global Rubraca Ovarian Market Forecast by Line Therapy
Table 13: Global Rubraca Ovarian Market Forecast by Line Therapy (2017-2025)
2.2.7 Global Zejula Market Forecast by Value
Table 14: Global Zejula Market Forecast by Value (2017-2025)
2.2.8 Global Zejula Market Forecast by Cancer Type
Table 15: Global Zejula Market Forecast by Cancer Type (2017-2025)
2.2.9 Global Zejula Ovarian Market Forecast by Line Therapy
Table 16: Global Zejula Ovarian Market Forecast by Line Therapy (2017-2025)
3. Regional Market
3.1 The U.S.
3.1.1 The U.S. Ovarian Cancer Incidence Forecast
Table 17: The U.S. Ovarian Cancer Incidence Forecast (2017-2025)
3.1.2 The U.S. Ovarian PARP Market Forecast by Value
Table 18: The U.S. Ovarian PARP Market Forecast by Value (2017-2025)
3.1.3 The U.S. Ovarian Patients PARP Inhibitors Forecast by Drug
Table 19: The U.S. Ovarian New Patients PARP Inhibitors Forecast by Drug (2017-2025)
3.1.4 The U.S. Ovarian Cancer Patients Receiving PARP by Line Therapy
Table 20: The U.S. Ovarian Cancer New Patients Receiving PARP by Line Therapy (2017-2025)
3.1.5 The U.S. Rubraca Market Forecast
Table 21: The U.S. Rubraca Market Forecast (2017-2025)
3.1.6 The U.S. Zejula Market Forecast
Table 22: The U.S. Zejula Market Forecast (2017-2025)
3.2 European Union
3.2.1 EU Ovarian Cancer Incidence Forecast
Table 23: EU Ovarian Cancer Incidence Forecast (2017-2025)
3.2.2 EU Rubraca Market Forecast
Table 24: EU Rubraca Market Forecast (2017-2025)
3.2.3 EU/ROW Zejula Market Forecast
Table 25: EU/ROW Zejula Market Forecast (2017-2025)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Cancer Cases
Table 26: Global New Cancer Cases (2012-2020)
4.1.2 Rising Healthcare Expenditure
Table 27: Global Healthcare Expenditure Per Capita (2013-2017)
4.1.3 Increased Ageing Population
Table 28: Global Ageing Population (2013-2017)
4.1.4 Increasing GDP Per Capita
Table 29: Global GDP Per Capita (2013-2017)
4.1.5 Vast Unmet Medical Need
4.2 Key Trends & Developments
4.2.1 Combinations of PARP Inhibitors and Immunotherapy
Table 30: Current Trials of PARP/IO Combinations (2017)
4.2.2 Development of Ovarian Cancer Diagnosis Methods and Biomarkers
Table 31: Biomarkers Used in Ovarian Cancer (2017)
4.2.3 Strong Research & Development Efforts by Companies
Table 32: R&D Expenditure of Companies (2016/2017)
4.2.4 Increasing Awareness of Early Diagnosis and Treatment of Disease
4.3 Challenges
4.3.1 Side Effects of PARP Inhibitors
4.3.2 Resistance to PARP Inhibitors
4.3.3 Regulatory Challenges
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
Table 33: Key Players - Revenue & Market Cap Comparison (2016/2017)
5.1.2 PARP Inhibitor Development by Company
Table 34: PARP Inhibitor Development by Company (2017)
6. Company Profiles
6.1 Tesaro Inc.
6.1.1 Business Overview
Table 35: Tesaro Inc. Product Pipeline (2017)
6.1.2 Financial Overview
Table 36: Tesaro Inc. Revenue and Net Loss (2012-2016)
6.1.3 Business Strategies
Table 37: Tesaro Inc. R&D Expenditure (2012-2016)
6.2 Clovis Oncology
6.2.1 Business Overview
Table 38: Clovis Oncology Product Pipeline (2017)
6.2.2 Financial Overview
Table 39: Clovis Oncology Revenue and Net Loss (2012-2016)
6.2.3 Business Strategies
Table 40: Clovis Oncology R&D Expenditure (2014-2016)
6.3 AstraZeneca
6.3.1 Business Overview
Table 41: AstraZeneca Revenue by Segments (2017)
Table 42: AstraZeneca Oncology Product Pipeline (2017)
6.3.2 Financial Overview
Table 43: Revenue and Net Profit (2013-2017)
6.3.3 Business Strategies
6.4 Abbvie Inc.
6.4.1 Business Overview
Table 44: Abbvie Inc. Revenue by Geographic (2017)
Table 45: Abbvie Oncology Product Pipeline (2017)
6.4.2 Financial Overview
Table 46: Abbvie Inc. Revenue and Net Earnings (2013-2017)
6.4.3 Business Strategies
Table 47: Abbvie Inc. R&D Expenditure (2014-2017)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report